Page last updated: 2024-08-16

salmeterol xinafoate and Cystic Fibrosis

salmeterol xinafoate has been researched along with Cystic Fibrosis in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (25.00)18.2507
2000's5 (62.50)29.6817
2010's1 (12.50)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Couriel, J; Evans, HJ; Halfhide, C2
Balossier, G; Coraux, C; Delavoie, F; Michel, J; Milliot, M; Molinari, M; Zahm, JM1
Bebok, Z; Collawn, JF; Matalon, S1
D'Andria, M; Salvatore, D1
Colombo, JL; Hordvik, NL; Judy, CG; Sammut, PH2
Bargon, J; Buhl, R; Dauletbaev, N; Viel, K; Wiewrodt, R1

Reviews

2 review(s) available for salmeterol xinafoate and Cystic Fibrosis

ArticleYear
WITHDRAWN: Inhaled bronchodilators for cystic fibrosis.
    The Cochrane database of systematic reviews, 2016, Feb-11, Volume: 2

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Bronchial Hyperreactivity; Bronchodilator Agents; Child; Cystic Fibrosis; Humans; Ipratropium; Randomized Controlled Trials as Topic; Salmeterol Xinafoate

2016
Inhaled bronchodilators for cystic fibrosis.
    The Cochrane database of systematic reviews, 2005, Oct-19, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Albuterol; Bronchial Hyperreactivity; Bronchodilator Agents; Child; Cystic Fibrosis; Humans; Ipratropium; Randomized Controlled Trials as Topic; Salmeterol Xinafoate

2005

Trials

4 trial(s) available for salmeterol xinafoate and Cystic Fibrosis

ArticleYear
Effects of salmeterol on arterial oxyhemoglobin saturations in patients with cystic fibrosis.
    Pediatric pulmonology, 2002, Volume: 34, Issue:1

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Cystic Fibrosis; Female; Humans; Hypoxia; Male; Oxyhemoglobins; Salmeterol Xinafoate

2002
Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis.
    Pediatric pulmonology, 2002, Volume: 34, Issue:4

    Topics: Adolescent; Adult; Albuterol; Anti-Bacterial Agents; Blood Pressure; Bronchodilator Agents; Cross-Over Studies; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Middle Aged; Pilot Projects; Pulse; Reference Values; Salmeterol Xinafoate; Spirometry; Time Factors; Vital Capacity

2002
Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients.
    The European respiratory journal, 1997, Volume: 10, Issue:10

    Topics: Administration, Inhalation; Adrenergic beta-Agonists; Adult; Albuterol; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Male; Middle Aged; Peak Expiratory Flow Rate; Prognosis; Prospective Studies; Respiratory Function Tests; Salmeterol Xinafoate; Statistics, Nonparametric; Treatment Outcome

1997
Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis.
    Pediatric pulmonology, 1999, Volume: 27, Issue:1

    Topics: Administration, Inhalation; Adolescent; Adrenergic beta-Agonists; Adult; Albuterol; Cross-Over Studies; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Forced Expiratory Volume; Genotype; Hospitalization; Humans; Male; Pulmonary Ventilation; Salmeterol Xinafoate; Spirometry; Treatment Outcome

1999

Other Studies

2 other study(ies) available for salmeterol xinafoate and Cystic Fibrosis

ArticleYear
Salmeterol restores secretory functions in cystic fibrosis airway submucosal gland serous cells.
    American journal of respiratory cell and molecular biology, 2009, Volume: 40, Issue:4

    Topics: Albuterol; Cell Line; Cell Polarity; Chlorides; Colforsin; Cyclic AMP; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Electrophysiological Phenomena; Epithelial Cells; Exocytosis; Humans; Intracellular Space; Ions; Muramidase; Salmeterol Xinafoate; Secretory Vesicles; Serous Membrane; Trachea

2009
Search and rescue: finding ways to correct deltaF508 CFTR.
    American journal of respiratory cell and molecular biology, 2009, Volume: 40, Issue:4

    Topics: Albuterol; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Humans; Ion Channel Gating; Models, Biological; Mutation; Protein Folding; Receptors, Adrenergic, beta-2; Salmeterol Xinafoate

2009